CardioComm Solutions Announces New CFO and Advisory Board Positions

Toronto, Ontario--(Newsfile Corp. - August 17, 2016) - Established medial electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company") today confirmed the appointment of Mr. John Overall as Chief Financial Officer ("CFO") and the naming of Dr. Robin Black and Dr. David Armstrong as advisors to the Company under the Company's newly-formed Advisory Board.

Mr. John Overall is a finance and legal professional with over 20 years of experience. He is a founding partner of New York City-based Paley Advisors and has worked closely with senior executives, founders, investment bankers and venture capitalists on strategic planning issues in software, medical devices, clean/alternative energy and oil and gas sectors. Mr. Overall has also served as senior advisor to Westbridge Investments and Carrick Bend Capital, with a focus on venture capital and private equity deals, he has consulted with start-up technology companies such as OcuSense, Inc. and Code Inc., has held senior analyst roles at the Technology Services Group at Hewlett Packard with a focus on global product introduction, and served as an analyst at Acer, Inc. with a focus on venture capital deal support and fund accounting. 

Through the Company's 17 years of selling ECG management and device connectivity solutions into the medical community, a wide network of collaborators and advisors was formed with clients and technology collaborators. CardioComm Solutions will now use select medical and industry advisors through a formal Advisory Board to coincide with the Company's intention to actively engage the new business dimension of providing connectivity innovations to meet consumer demand for credible mobile devices to be used in medical/health monitoring in the sports, wellness and health markets. The first two advisors named to the Company's Advisory Board are Dr. David Armstrong (Ottawa, ON) and Dr. Robin Black (Victoria, BC).

Dr. David Armstrong has provided executive leadership to achieve financial, fund-raising, marketing, strategic partnering, IP and communication goal attainment in public and private health sector environments. He has served at the executive level guiding clinical affairs portfolios in North American medical diagnostics, wound management and clinical interventions (training/simulation) areas and has been involved in formulating strategies leading to successful corporate acquisitions. Dr. Armstrong is currently leading an e-technology initiative for the transfer of standardized diagnostic measures, auto-analytics/trending, from patient into hospital EMRs using secure real-time device connectivity including tablet technology. His recognized entrepreneurial leadership has been utilized by private and public sector Boards including involvement at the Executive Board level for one of Canada's top-ranked hospital research institutions (>$100 M/year successful grant capture).

Dr. Robin Black brings 35 years of experience in the medical device sector with experience in research, product development and investment, through the National Research Council Industrial Research Assistance Program. Specifically, he has 20 years supporting the development of early stage companies in the medical sector including medical informatics. He advised the former Alberta Stock Exchange on the development of an advisory board for early stage companies in the technology sector. In this context, he studied the challenges faced by medical and biotech companies raising public and private financing.

CardioComm Solutions continues to manage increased cross-technical collaborative and co-marketing activities and reports that the new additions will increase the Company's capacity to expand its market presence as a provider of innovative medical device connectivity solutions by:

• seeking connectivity relationships with domestic and overseas firms that develop medical monitoring technologies;

• seeking opportunities for integration of new devices as HeartCheck™-branded and SMART Monitoring-affiliated products;

• assisting companies in applying for medical device clearances for over-the-counter (OTC) and Rx use of their medical devices in the North American markets; and

• leveraging new medical device relationships to expand use of CardioComm Solutions' own SMART Monitoring cardiac rhythm and ECG reading services in and outside of North America.

To learn more about the CardioComm Solutions' products, for more information about the company's appointments and for further updates regarding HeartCheck™ ECG device integrations, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com.

About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions is headquartered in Toronto, Ontario, Canada. CardioComm Solutions has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), Australia (TGA), the USA (FDA), China (CFDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investor.relations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.